BCL partner, John Binns writes for Analytical Cannabis on the current legal landscape of the UK cannabis industry and potential developments to come.
Here’s an extract from the article*:
“Until recently at least, the casual observer could be forgiven for thinking that the position was rather more nuanced than it is, thanks to eye-catching headlines in autumn last year to the effect that medical cannabis had been legalized.
In reality, the limited exception previously available only to GW Pharma’s Sativex medication had been joined by another, more generally worded exception: for “cannabis-based medicinal products” (CBMPs), though only where prescribed by a specialist clinician (not just a general practitioner), or granted a marketing authorisation by our Medicines and Healthcare products Regulatory Agency (MHRA). “
*This article was originally published by Analytical Cannabis on 17th July 2019. You can read the full version here.